BIIB — BIOGEN INC (Healthcare >> Drug Manufacturers - General)
BIIB FAQ
What is BIIB's P/E ratio?
BIOGEN INC (BIIB) currently trades at a P/E ratio of 20.41.
What is BIIB's ROE?
BIOGEN INC reports a Return on Equity (ROE) of 7.36%.
What is BIIB's dividend yield?
BIOGEN INC offers a dividend yield of 0.00%.
What is BIIB's Deepscope Quality Score?
Deepscope rates BIIB's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BIIB?
Deepscope's AI Timing Score for BIIB is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BIIB belong to?
BIOGEN INC is classified under the Healthcare >> Drug Manufacturers - General sector on the NASDAQ exchange.
|
USD 195.34
Price
-1.11
(-0.57%)
Day Change
|
|
|---|
BIIB, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
1704
|
| Magic Formula Rank by ROE |
1704
|
| Magic Formula Rank by ROIC |
1728
|
| Price | 195.34 |
| PBV / Sector |
1.55 / 2.84
GOOD
|
| Earning Per Share | 9.24 |
| PE / Sector |
20.41 / 24.53
|
| PEG or PE/Growth / Sector |
-1.43 / 0.08
|
| Average 1M Daily Value |
204.46 M
GREAT
|
| Average 1W Daily Value |
150.23 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
58% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | BIIB |
| Name | BIOGEN INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 147.64 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 29,003.31 / 241,254.65 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 225 Binney Street, Cambridge, MA, United States, 02142
Phone: 617 679 2000
Website: https://www.biogen.com
Employees: 7,500
Description: Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google